Abstract
Background. A 63-year-old woman with chronic myeloid leukemia (CML) received treatment with interferon (IFN)-α for 6 years. After achieving a complete cytogenetic response that was repetitively documented, IFN-α treatment was stopped. Despite maintenance of a complete cytogenetic response, a progressive rise of the BCR–ABL1 transcript was detected and loss of major molecular response occurred about 2 years after stopping IFN-α therapy. Disease remained at molecular level.
Investigations. Peripheral blood quantitative real-time PCR every 3 months and periodical bone marrow aspirate were performed to monitor disease.
Diagnosis. Chronic-phase, Philadelphia-positive CML that was still detectable after complete cytogenic response 2 years after cessation of IFN-α therapy.
Management. The patient was treated with a target immune approach receiving a therapeutic vaccine that consisted of an immunogenic 25-mer b2a2 breakpoint-derived peptide (CMLb2a2–25) with binding properties for several HLA–DR molecules. After nine boosts of vaccine the patient developed an adequate b2a2–25 peptide-specific CD4+ T-cell response and BCR–ABL1 transcript started to decline in peripheral blood. No hematological or extrahematological effects were documented during therapy. At the last evaluation, 39 months since vaccinations commenced, the patient is in complete molecular response with an undetectable level of BCR–ABL1 transcript both in peripheral blood and in bone marrow and she continues to receive boosts of vaccine every 3 months as the only treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hehlmann, R., Hochhaus, A. & Baccarani, M. Chronic myeloid leukaemia. Lancet 370, 342–350 (2007).
Muller, M. C. et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 22, 96–102 (2008).
Kantarjian, H., Shiffer, C., Jones, D. & Cortes, J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 111, 1774–1780 (2008).
Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408–2417 (2007).
Quintas-Cardama, A., Kantarjian, H. & Cortes, J. Imatinib and beyond—exploring the full potential of targeted therapy for CML. Nat. Rev. Clin. Oncol. 6, 535–543 (2009).
de Lavallade, H. et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J. Clin. Oncol. 26, 3358–3363 (2008).
Bonifazi, F. et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 98, 3074–3081 (2001).
Beelen, D. W. & Schaefer, U. W. Allogeneic stem cell transplants in chronic myeloid leukemia. Ann. Hematol. 81 (Suppl. 2), S45–S46 (2002).
Hochhaus, A. et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23, 1054–1061 (2009).
Rousselot, P. et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109, 58–60 (2007).
Bocchia, M. et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365, 657–662 (2005).
Rojas, J. M., Knight, K., Wang, L. & Clark, R. E. Clinical evaluation of BCR–ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 21, 2287–2295 (2007).
Jain, N. et al. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer 115, 3924–3934 (2009).
Bocchia, M. et al. BCR–ABL derived peptide vaccine in chronic myeloid leukemia patients with molecular minimal residual disease during imatinib: interim analysis of a phase 2 multicenter GIMEMA CML Working Party Trial. ASH Annual Meeting Abstracts 114, 648 (2009).
Radich, J. P. How I monitor residual disease in chronic myeloid leukemia. Blood 114, 3376–3381 (2009).
Burchert, A. et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J. Clin. Oncol. 28, 1429–1435 (2010).
Bocchia, M. et al. CMLVAX100 peptide vaccinations induce peptide specific “cytotoxic” CD4+ T Cells (CD4+CTLs) in chronic myeloid leukemia patients: new insights about peptide vaccine-mediated antitumor response. ASH Annual Meeting Abstracts 112, 3209 (2008).
Acknowledgements
This study was supported by grants from SIENAIL (Associazione Italiana Leucemie, Linfomi e Mielomi Sezione di Siena). The authors thank N. S. Gaonkar for kind assistance in language editing of the manuscript. Written consent for publication was obtained from the patient.
Author information
Authors and Affiliations
Contributions
M. Bocchia, L. Aprile, M. Ippoliti, R. Crupi and A. Gozzetti researched the data for the article. M. Bocchia, M. Defina, L. Aprile, M. Ippoliti, R. Crupi, M. Rondoni and A. Gozzetti provided a substantial contribution to discussions of the content. M. Bocchia, M. Defina, M. Rondoni and F. Lauria contributed to writing the article. M. Bocchia, M. Defina, L. Aprile, M. Ippoliti, M. Rondoni, A. Gozzetti and F. Lauria contributed to the review and/or editing of the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Bocchia, M., Defina, M., Aprile, L. et al. Complete molecular response in CML after p210 BCR–ABL1-derived peptide vaccination. Nat Rev Clin Oncol 7, 600–603 (2010). https://doi.org/10.1038/nrclinonc.2010.141
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.141
This article is cited by
-
Therapeutic cancer vaccines
Nature Reviews Cancer (2021)
-
Targeting public neoantigens for cancer immunotherapy
Nature Cancer (2021)
-
Cancer immune therapy for myeloid malignancies: present and future
Seminars in Immunopathology (2019)
-
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
Molecular Cancer (2018)
-
New insights into antigen specific immunotherapy for chronic myeloid leukemia
Cancer Cell International (2012)